At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 636 enrolled
Drug / intervention
pramlintide acetate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.
In Brief
A Phase 2 clinical trial evaluating pramlintide acetate, metreleptin, and 2 other interventions for Overweight and Obesity. Completed, enrolled 636 participants across 36 sites.
Detailed Summary
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionApr 2009
Study CompletionOct 2009
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.2 years ago
Interventions
pramlintide acetatedrug
subcutaneous injection, twice a day
metreleptindrug
subcutaneous injection, twice a day
placebo-Pdrug
subcutaneous injection, twice a day
placebo-Mdrug
subcutaneous injection, twice a day